• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?

作者信息

Negri Francesca, Porta Camillo

机构信息

Medical Oncology Unit, University Hospital of Parma, Parma.

Department of Biomedical Sciences & Human Oncology, University of Bari 'Aldo Moro', and Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

出版信息

Oncol Rev. 2021 Sep 22;15(2):564. doi: 10.4081/oncol.2021.564. eCollection 2021 Sep 21.

DOI:10.4081/oncol.2021.564
PMID:34667489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8477309/
Abstract
摘要

相似文献

1
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?多纳非尼用于中国晚期肝细胞癌（HCC）患者：真的是一种新的标准治疗方法，还是我们应该改变HCC药物研发的模式？
Oncol Rev. 2021 Sep 22;15(2):564. doi: 10.4081/oncol.2021.564. eCollection 2021 Sep 21.
2
Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study.解毒颗粒（一种复方中药制剂）与索拉非尼治疗晚期肝细胞癌的疗效相当：一项前瞻性多中心队列研究。
J Integr Med. 2020 Jul;18(4):319-325. doi: 10.1016/j.joim.2020.05.003. Epub 2020 May 28.
3
[Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].[液相色谱-串联质谱法同时测定人血浆中多纳非尼及其N-氧化物代谢物]
Yao Xue Xue Bao. 2017 Mar;52(3):443-8.
4
Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.晚期肝细胞癌：一家地区癌症中心48例病例的经验
Indian J Cancer. 2017 Jul-Sep;54(3):526-529. doi: 10.4103/ijc.IJC_373_17.
5
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.卡博替尼与瑞戈非尼治疗晚期肝细胞癌的疗效比较。
Adv Ther. 2020 Jun;37(6):2678-2695. doi: 10.1007/s12325-020-01378-y. Epub 2020 May 18.
6
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.普伐他汀联合索拉非尼不能改善晚期肝细胞癌的生存。
J Hepatol. 2019 Sep;71(3):516-522. doi: 10.1016/j.jhep.2019.04.021. Epub 2019 May 22.
7
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.索拉非尼联合或不联合经动脉化疗栓塞治疗晚期肝细胞癌患者的 III 期 STAH 试验。
J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.
8
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.不可切除肝细胞癌的治疗选择，重点是使用钇-90树脂微球的选择性内放射治疗（SIRT）
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
9
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.索拉非尼在晚期肝细胞癌中的疗效
Oncologist. 2016 Sep;21(9):1113-20. doi: 10.1634/theoncologist.2015-0478. Epub 2016 May 16.
10
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.阿根廷的中晚期肝细胞癌：治疗和生存分析。
World J Gastroenterol. 2019 Jul 21;25(27):3607-3618. doi: 10.3748/wjg.v25.i27.3607.

引用本文的文献

1
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives.批准用于晚期肝细胞癌全身治疗的小分子酪氨酸激酶抑制剂：最新进展与未来展望。
Discov Oncol. 2024 Jul 3;15(1):259. doi: 10.1007/s12672-024-01110-0.
2
The lncRNA lnc-TSI antagonizes sorafenib resistance in hepatocellular carcinoma via downregulating miR-4726-5p expression and upregulating KCNMA1 expression.长链非编码 RNA lnc-TSI 通过下调 miR-4726-5p 表达和上调 KCNMA1 表达拮抗肝癌索拉非尼耐药。
J Mol Histol. 2024 Feb;55(1):83-96. doi: 10.1007/s10735-023-10173-2. Epub 2024 Jan 2.
3
Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.含氘药物治疗癌症的最新进展。
Drug Des Devel Ther. 2022 Oct 4;16:3465-3472. doi: 10.2147/DDDT.S379496. eCollection 2022.
4
State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.分化型甲状腺癌靶向治疗的现状与未来方向
Int J Mol Sci. 2022 Mar 23;23(7):3470. doi: 10.3390/ijms23073470.

本文引用的文献

1
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.多纳非尼对比索拉非尼用于不可切除或转移性肝细胞癌的一线治疗：一项随机、开放标签、平行对照的 II/III 期试验。
J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29.
2
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
3
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
4
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
5
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.乐伐替尼治疗肝细胞癌：从临床前机制到抗癌治疗。
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188391. doi: 10.1016/j.bbcan.2020.188391. Epub 2020 Jul 10.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.一项评估口服多纳非尼在晚期实体瘤患者中的 I 期剂量递增、药代动力学和食物影响的研究。
Cancer Chemother Pharmacol. 2020 Mar;85(3):593-604. doi: 10.1007/s00280-020-04031-1. Epub 2020 Feb 1.
8
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient.晚期肝细胞癌患者的医学治疗：问题不在于选对药物，而在于选对患者。
Hepatology. 2019 Jul;70(1):429-430. doi: 10.1002/hep.30521. Epub 2019 Mar 13.
9
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.非酒精性脂肪性肝炎的发病机制：营养过剩的代谢并发症如何导致脂毒性和促炎脂肪性肝病。
Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.
10
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.